90 related articles for article (PubMed ID: 18338433)
1. European license for Viracept re-established by EC.
AIDS Patient Care STDS; 2007 Nov; 21(11):891. PubMed ID: 18338433
[No Abstract] [Full Text] [Related]
2. Viracept contaminated in Europe.
AIDS Patient Care STDS; 2007 Jul; 21(7):521. PubMed ID: 17651033
[No Abstract] [Full Text] [Related]
3. EMS in Viracept--the course of events in 2007 and 2008 from the non-clinical safety point of view.
Müller L; Singer T
Toxicol Lett; 2009 Nov; 190(3):243-7. PubMed ID: 19857794
[TBL] [Abstract][Full Text] [Related]
4. Recall of AIDS drug hits world's poorest patients.
AIDS Read; 2007 Sep; 17(9):439. PubMed ID: 17902224
[No Abstract] [Full Text] [Related]
5. FDA notifications. FDA provides more info in response to Viracept recall.
AIDS Alert; 2007 Nov; 22(11):129-31. PubMed ID: 18411458
[No Abstract] [Full Text] [Related]
6. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
7. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
Lutz WK
Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
[TBL] [Abstract][Full Text] [Related]
8. Viracept recommended for reinstatement in Europe.
AIDS Patient Care STDS; 2007 Oct; 21(10):780. PubMed ID: 17992722
[No Abstract] [Full Text] [Related]
9. What happened: the chemistry side of the incident with EMS contamination in Viracept tablets.
Gerber C; Toelle HG
Toxicol Lett; 2009 Nov; 190(3):248-53. PubMed ID: 19857795
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies on inhibitors of HIV protease: a target for drug design.
Jayaraman S; Shah K
In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
[TBL] [Abstract][Full Text] [Related]
11. [European registration of drugs; consequences for prescriber and patient].
van Grootheest AC
Ned Tijdschr Geneeskd; 1997 Jun; 141(26):1305-6. PubMed ID: 9380178
[No Abstract] [Full Text] [Related]
12. [The European regulation REACH: role of the toxicologist and the occupational specialist].
Cavallo DM; Sesana G; Colosio C; Moretto A
G Ital Med Lav Ergon; 2008; 30(3 Suppl):82-9. PubMed ID: 19288795
[No Abstract] [Full Text] [Related]
13. Europe's drug lottery.
Alcorn K
J Int Assoc Physicians AIDS Care; 1996 Feb; 2(2):33. PubMed ID: 11363338
[TBL] [Abstract][Full Text] [Related]
14. Caution regarding nelfinavir use in children and pregnant women.
AIDS Clin Care; 2007 Nov; 19(11):96. PubMed ID: 18399001
[TBL] [Abstract][Full Text] [Related]
15. Nelfinavir induces TRAIL receptor upregulation in ovarian cancer cells.
Brüning A; Vogel M; Burger P; Rahmeh M; Gingelmaier A; Friese K; Lenhard M; Burges A
Biochem Biophys Res Commun; 2008 Dec; 377(4):1309-14. PubMed ID: 19000651
[TBL] [Abstract][Full Text] [Related]
16. Sluggish generics entry prompts calls for European patent reform.
Laursen L
Nat Med; 2009 Nov; 15(11):1239. PubMed ID: 19893542
[No Abstract] [Full Text] [Related]
17. Drop in trough blood concentrations of tacrolimus after switching from nelfinavir to fosamprenavir in four HIV-infected liver transplant patients.
Pea F; Tavio M; Pavan F; Londero A; Bresadola V; Adani GL; Furlanut M; Viale P
Antivir Ther; 2008; 13(5):739-42. PubMed ID: 18771060
[TBL] [Abstract][Full Text] [Related]
18. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
Bihani SC; Das A; Prashar V; Ferrer JL; Hosur MV
Biochem Biophys Res Commun; 2009 Nov; 389(2):295-300. PubMed ID: 19720046
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
20. Europe issues proposals to bring drugs to market faster.
Watson R
BMJ; 2012 Mar; 344():e1650. PubMed ID: 22391819
[No Abstract] [Full Text] [Related]
[Next] [New Search]
